^

Original-Research: Ikonisys SA - von Sphene Capital GmbH

Einstufung von Sphene Capital GmbH zu Ikonisys SA

Unternehmen: Ikonisys SA

ISIN: FR00140048X2

Anlass der Studie: Update Report

Empfehlung: Buy

seit: 06.02.2024

Kursziel: EUR 6,30 (bisher: EUR 4,50)

Kursziel auf Sicht von: 36 Monate

Letzte Ratingänderung: -

Analyst: Peter Thilo Hasler, CEFA

Creating a leading player in cancer diagnostics

 

Only weeks after Ikonisys entered a strategic partnership with Biocare

Medical, the company made the next strategic step in business development

by announcing the takeover of Hospitex, an Italian-based cytology company

specialising in oncological diagnostics. According to the company, Hospitex

has developed a unique ecosystem around a technology called Nephelometric

Smart Technology (NST). Central to the ecosystem is CYTOfast Plus, which is

claimed to be the most advanced processing solution to produce filter-less,

standardized, single-layer liquid based cytology (LBC) diagnostic slides.

While competitor technologies were originally designed only for the

so-called Pap test, a screening test for cervical cancer, the patent

protected NST is the only certified technology for the entire cytology

universe and for all target organs, according to the company. We believe

that Hospitex could prove a perfect fit to extend Ikonisys' value chain and

should significantly support the company's growth and profitability in the

years ahead. After adjusting our financial model to the acquisition and the

new number of shares, the intrinsic value derived from our three-stage DCF

entity model increases to EUR 6.30 from EUR 4.50 per share (base case

scenario). We reiterate our Buy rating.

Die vollständige Analyse können Sie hier downloaden:

http://www.more-ir.de/d/28825.pdf

Kontakt für Rückfragen

Peter Thilo Hasler, CEFA

+49 (89) 74443558/ +49 (152) 31764553

peter-thilo.hasler@sphene-capital.de

-------------------übermittelt durch die EQS Group AG.-------------------

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw.

Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung

oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

°